Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients

Shin,Mi  Kyung; Kim,Jeong  Won; Min,Soo  Kee; Lee,Dong  Jin; Kim,Jin  Hwan; Lee,Seung  Chul; Chung,Bong  Wha; Ju,Young  Su

doi:10.3892/ol.2015.3401

Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients

Authors:
- Mi Kyung Shin
- Jeong Won Kim
- Soo Kee Min
- Dong Jin Lee
- Jin Hwan Kim
- Seung Chul Lee
- Bong Wha Chung
- Young Su Ju
View Affiliations

Affiliations: Department of Pathology, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Yeongdeungpo-gu, Seoul 150‑950, Republic of Korea, Department of General Surgery, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Yeongdeungpo-gu, Seoul 150‑950, Republic of Korea, Department of Pathology, Hallym University Sacred Heart Hospital, Anyang‑si, Gyeonggi‑do 431‑796, Republic of Korea, Department of Otorhinolaryngology‑Head and Neck Surgery, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Yeongdeungpo-gu, Seoul 150‑950, Republic of Korea, Department of Occupational and Environmental Medicine, Hallym University Sacred Heart Hospital, Anyang‑si, Gyeonggi‑do 431‑796, Republic of Korea
Published online on: June 22, 2015 https://doi.org/10.3892/ol.2015.3401
Pages: 1882-1888

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The BRAF (V600E) mutation is the most prevalent type of genetic alteration that has been identified in papillary thyroid carcinoma (PTC); in addition, previous immunohistochemical studies have revealed the overexpression of p53 protein in PTC. The aim of the present study was to investigate the prevalence of the BRAF (V600E) mutation and the expression of p53 in PTC, as well as to determine any associations between these two factors and the clinicopathological features of PTC. The study was performed on 66 PTC patients who underwent surgical tumor resection between January and December 2012. Polymerase chain reaction‑based DNA amplification was used to analyze extracted DNA from the tumor specimens in order to determine the prevalence of the BRAF (V600E) mutation. In addition, immunohistochemical analysis was employed in order to evaluate the protein expression of p53 in sections of tumor tissue. Furthermore, statistical analysis was performed in order to determine any associations among the BRAF (V600E) mutation prevalence, p53 overexpression and the clinicopathological features of PTC patients, including age, gender, tumor size, multiplicity, lymph node metastasis and extrathyroidal extension. The results revealed that the BRAF (V600E) mutation was observed in 50 (75.8%) of the 66 PTC patients and overexpression of p53 was found in 52 (78.8%) of 66 cases. No significant correlations were observed between the BRAF (V600E) mutation or p53 protein overexpression and the clinicopathological features of patients. However, the BRAF (V600E) mutation demonstrated noteworthy, but non‑significant, correlations with the overexpression of p53 (P=0.0854) and extrathyroidal extension (P=0.0661). In addition, a significant correlation was observed between lymph node metastasis and bilaterality (P=0.0280). In conclusion, the present study demonstrated that the BRAF (V600E) mutation and overexpression of p53 were not significantly correlated with clinicopathological features of PTC, although notable associations were identified between BRAF (V600E) mutation and overexpression of p53 as well as extrathyroidal extension. In addition, lymph node metastasis was significantly associated with bilaterality.

View Figures

View References

1	Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P and Preusser M: Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 36:844–850. 2012. View Article : Google Scholar : PubMed/NCBI
2	Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, et al: Papillary microcarcinoma of the thyroid: Clinical characteristics and BRAF (V600E) mutational status of 977 cases. Ann Surg Oncol. 20:2266–2273. 2013. View Article : Google Scholar : PubMed/NCBI
3	Balta AZ, Filiz AI, Kurt Y, Sucullu I, Yucel E and Akin ML: Prognostic value of oncoprotein expressions in thyroid papillary carcinoma. Med Oncol. 29:734–741. 2012. View Article : Google Scholar : PubMed/NCBI
4	Morita N, Ikeda Y and Takami H: Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J Surg. 32:2617–2622. 2008. View Article : Google Scholar : PubMed/NCBI
5	Zafon C, Obiols G, Castellvi J, Tallada N, Baena JA, Simo R, et al: Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology. 50:225–231. 2007. View Article : Google Scholar : PubMed/NCBI
6	Hamzany Y, Soudry E, Strenov Y, Lipschitz N, Segal K, Hadar T, et al: Early death from papillary thyroid carcinoma. Am J Otolaryngol. 33:104–108. 2012. View Article : Google Scholar : PubMed/NCBI
7	Horie S, Maeta H, Endo K, Ueta T, Takashima K and Terada T: Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features. Pathol Int. 51:11–15. 2001. View Article : Google Scholar : PubMed/NCBI
8	Parameswaran R, Brooks S and Sadler GP: Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg. 8:186–193. 2010. View Article : Google Scholar : PubMed/NCBI
9	Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, et al: BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 36:310–317. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kim KH, Kang DW, Kim SH, Seong IO and Kang DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 45:818–821. 2004. View Article : Google Scholar : PubMed/NCBI
11	Musholt TJ, Schonefeld S, Schwarz CH, Watzka FM, Musholt PB, Fottner C, et al: Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation. Langenbecks Arch Surg. 395:877–883. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ahn D, Park JS, Sohn JH, Kim JH, Park SK, Seo AN and Park JY: BRAF (V600E) mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx. 39:198–203. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ricarte-Filho J, Ganly I, Rivera M, Katabi N, Fu W, Shaha A, et al: Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases and extra-nodal extension. Thyroid. 22:575–584. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kurt B, Yalcin S, Alagoz E, Karslıoğlu Y, Yigit N, Gunal A, et al: The relationship of the BRAF (V600E) Mutation and the established prognostic factors in papillary thyroid carcinomas. Endocr Pathol. 23:135–140. 2012. View Article : Google Scholar : PubMed/NCBI
15	Prescott JD, Sadow PM, Hodin RA, Le LP, Gaz RD, Randolph GW, et al: BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery. 152:984–990. 2012. View Article : Google Scholar : PubMed/NCBI
16	Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, et al: The BRAF (V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 97:4390–4398. 2012. View Article : Google Scholar : PubMed/NCBI
17	Daglar-Aday A, Toptas B, Ozturk T, Seyhan F, Saygili N, Eronat A, et al: Investigation of BRAF V600E mutation in papillary thyroid carcinoma and tumor-surrounding nontumoral tissues. DNA Cell Biol. 32:13–18. 2013. View Article : Google Scholar : PubMed/NCBI
18	Jeong D, Jeong Y, Park JH, Han SW, Kim SY, Kim YJ, et al: BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR. Ann Surg Oncol. 20:759–766. 2013. View Article : Google Scholar : PubMed/NCBI
19	Brahma B, Yulian ED, Ramli M, Setianingsih I, Gautama W, Brahma P, et al: Surgical perspective of T1799A BRAF mutation diagnostic value in papillary thyroid carcinoma. Asian Pac J Cancer Prev. 14:31–37. 2013. View Article : Google Scholar : PubMed/NCBI
20	Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al: Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 309:1493–1501. 2013. View Article : Google Scholar : PubMed/NCBI
21	Gauchotte G, Philippe C, Lacomme S, Leotard B, Wissler MP, Allou L, et al: BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology. 43:447–452. 2011. View Article : Google Scholar : PubMed/NCBI
22	Park KY, Koh JM, Kim YI, Park HJ, Gong G, Hong SJ, et al: Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin Endocrinol (Oxf). 49:317–323. 1998. View Article : Google Scholar : PubMed/NCBI
23	Liu MC and Gelmann EP: P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol. 29:246–257. 2002. View Article : Google Scholar : PubMed/NCBI
24	Omar E, Madhavan M and Othman NH: Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications. Pathology. 36:152–159. 2004. View Article : Google Scholar : PubMed/NCBI
25	Dellis RA, Lloyd RV, Heitz U and Eng C: Tumours of endocrine organsPathology and Genetics. International Agency for Research on Cancer Press; Lyon: pp. 57–66. 2004
26	Mitzner R: Neck Dissection Classification. http://emedicine.medscape.com/article/849834-overviewJune 9th–2015
27	Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL and Nikiforov YE: Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope. 123:1059–1064. 2013. View Article : Google Scholar : PubMed/NCBI
28	Min HS, Lee C and Jung KC: Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J Korean Med Sci. 28:534–541. 2013. View Article : Google Scholar : PubMed/NCBI
29	Smith RA, Salajegheh A, Weinstein S, Nassiri M and Lam AK: Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol. 42:500–506. 2011. View Article : Google Scholar : PubMed/NCBI
30	Cvejic D, Selemetjev S, Savin S, Paunovic I, Petrovic I and Tatic S: Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid. Pathology. 40:475–480. 2008. View Article : Google Scholar : PubMed/NCBI
31	Karlidag T, Cobanoglu B, Keles E, Alpay HC, Ozercan I, Kaygusuz I, et al: Expression of Bax, p53 and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol. 28:31–36. 2007. View Article : Google Scholar : PubMed/NCBI